The majority of this site is offered without collecting any personally identifiable information from our visitors. We collect personally identifiable information, such as name, address and e-mail, and non-personally identifiable demographic information (age, gender, etc.), only when you voluntarily submit it to us or you request information from us. We also collect non-personally identifiable aggregate information to learn more about areas of the site that are of the most interest to visitors, or to learn who visits the site. We may on occasion post non-personally identified messages we receive from visitors to our sites, such as comments about our products and company.
Only when you specifically request it will the information that we collect be used to respond to your questions, or to fulfill e-mail messaging programs, and notify visitors about new content or services on our Web sites. You will have the ability to opt-out from receiving marketing communications from CSL Entities at any time. If you wish to unsubscribe from any CSL marketing materials, you can manage your preferences via https://cslbehringpreferences.com/ or write to us at CSL Behring c/o Patient Services P.O. Box 1587 Jeffersonville, IN 47130 or by calling 833-436-0021, to tell us that you no longer wish to receive postal mail and/or e-mail. Please provide us with your exact name, postal address, and/or e-mail address. We will be sure your name is removed from our mailing list.
As many other companies do, we measure the performance of our Web site to improve and customize it to better serve your needs. During your visit, we automatically collect the following information about your computer and your visit:
We may use third parties to manage these performance measurements. However, we do not acquire information on the individual identity of any visitor. These third parties will be required to follow our privacy standards, to provide us only with aggregate information, to use the information collected only for the purposes for which the third party was retained by us, and to then destroy the information.
You may have the option to register to our site. If you do, we may retrieve your name, address, telephone number and e-mail address. Nothing will happen if you choose not to submit this information except that you may not obtain the functionality or receive information you requested.
At any time upon your request, we will delete or modify personal information that you provided earlier. If you want to review, update or delete your personal data, please sign in to make the desired changes. We will use personal information only for the purpose indicated to you when you provided it. We will not disclose, sell, rent or exchange this information to any other organization or entity unless you are first notified and expressly agree to it, or as otherwise required by law.
In addition to the uses and disclosures set forth above, we may also release personal information to third parties to comply with applicable legal requirements, such as in responding to a search warrant, subpoena, or court order, or complying with a statute, regulation, or other law; in special situations, such as in response to a physical threat to you or to others, or to protect our property or to otherwise defend or assert our legal rights; or in ways that we believe are consistent with government regulations, guidance, directions, and laws applicable to CSL Behring. In addition, we may cooperate with law enforcement authorities in investigating and prosecuting Web site visitors who violate our rules or engage in behavior that is harmful to other visitors or is illegal. Finally, in conjunction with a corporate sale, merger, dissolution, or acquisition, we may transfer your personal information to a third party in connection with that transaction.
CSL Behring recognizes the privacy concerns of parents and the importance of protecting the privacy of information collected from children. This Web site is operated primarily for the use of healthcare providers, adult consumers and caregivers, and is not designed or intended to attract children under the age of 13.
From time to time, we may offer an online program or activity that allows children under the age of 13 to participate. In such instances, we provide additional privacy protections.
Parents of children who participate in online activities that are open to children under 13 through this Web site can be confident that any personal information that is provided to this Web site will be collected and maintained in accordance with the Children's Online Privacy Protection Act (“COPPA”). We encourage parents to supervise their children's activities online and to participate with their children's online activities whenever possible. If you have questions or concerns about the Internet and privacy for children, we encourage you to visit https://www.ftc.gov/news-events/press-releases/2012/12/ftc-strengthens-kids-privacy-gives-parents-greater-control-over.
At the present time, CSL Behring is not conducting any activities that are subject to the requirements of COPPA.
Maintaining security of personally identifiable information has our highest priority. We follow strict security procedures for safeguarding information and preventing unauthorized access. We protect information in our high-security data center and adhere to strict computer security standards. We have put in place privacy protection control systems designed to ensure that information about you remains safe and secure. Only authorized CSL Behring employees are permitted to have access to this information and such access is limited by need.
You may disable the cookie feature on your computer or set it to alert you when cookies are being sent by using the preferences on your browser. If you choose to disable cookies, however, we may not be able to provide you with certain features (e.g., customized delivery of information) available on our Web site. Further information about cookies can be found here. Further information about Google Analytics can be found here, and you may opt-out of Google Analytics here.
Generally, online social media resources are interactive tools that enable you to collaborate and share information with others. Social media resources include but are not limited to social networks, discussion boards, bulletin boards, blogs, wikis, and referral functions to share web site content and tools with a friend or colleague. CSL Behring may collect personal information from you to enable you to use online social media resources we may occasionally offer to you. CSL Behring may also enable you to use these social media resources to post or share personal information with others. When using social media resources carefully consider what information about yourself you choose to share with others.
In addition to the uses described above for the CSL Behring websites, some CSL Behring Web sites and online resources are specifically designed to be compatible and used on mobile computing devices. Mobile versions of CSL Behring Web sites may require that you log in with a user account for that Web site. Information about your use of the mobile version of the Web site will be associated with your user account. Further, some of our Web sites and online resources may enable you to download an application, widget or other tool that you can use on your mobile or other computing device. Some of these tools may store information on your mobile or other device. These tools may transmit personal information to CSL Behring to enable you to access your user account and to enable CSL Behring to track use of these tools. Some of these tools may enable you to e-mail reports and other information from the tool. CSL Behring may use personal or non-identifiable information transmitted to CSL Behring to enhance these tools, to develop new tools, for quality improvement and as otherwise described in this Policy or in other notices CSL Behring provides.
We contract with third parties to provide services related to managing this Web site. In such cases, these third parties may have access to personal information. These third parties are required to follow our privacy standards and to use such personal information only in order to fulfill their responsibilities to us.
Important Safety Information
WARNING: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS
Patients being treated with Vitamin K antagonist therapy have underlying disease states that predispose them to thromboembolic events. Potential benefits of reversing VKA should be weighed against the risk of thromboembolic events, especially in patients with history of such events. Resumption of anticoagulation therapy should be carefully considered once the risk of thromboembolic events outweighs the risk of acute bleeding. Both fatal and nonfatal arterial and venous thromboembolic complications have been reported in clinical trials and postmarketing surveillance. Monitor patients receiving KCENTRA, and inform them of signs and symptoms of thromboembolic events. KCENTRA was not studied in subjects who had a thromboembolic event, myocardial infarction, disseminated intravascular coagulation, cerebral vascular accident, transient ischemic attack, unstable angina pectoris, or severe peripheral vascular disease within the prior 3 months. KCENTRA might not be suitable for patients with thromboembolic events in the prior 3 months.
KCENTRA is contraindicated in patients with known anaphylactic or severe systemic reactions to KCENTRA or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). KCENTRA is also contraindicated in patients with disseminated intravascular coagulation. Because KCENTRA contains heparin, it is contraindicated in patients with heparin-induced thrombocytopenia (HIT).
Hypersensitivity reactions to KCENTRA may occur. If patient experiences severe allergic or anaphylactic type reactions, discontinue administration and institute appropriate treatment.
In clinical trials, the most frequent (≥2.8%) adverse reactions observed in subjects receiving KCENTRA were headache, nausea/vomiting, hypotension, and anemia. The most serious adverse reactions were thromboembolic events, including stroke, pulmonary embolism and deep vein thrombosis.
KCENTRA is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.
KCENTRA®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA—eg, warfarin) therapy in adult patients with acute major bleeding or the need for urgent surgery or other invasive procedure. KCENTRA is for intravenous use only.
Please see full prescribing information for KCENTRA.
To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.